Alpine Immune Sciences, Inc.

Seagen Inc.

Stanford L Peng

Stacey R Dillon

Mark W Rixon

Joseph Leon Kuijper

Lawrence Evans

Daniel William Demonte

Che-Leung Law

Shyra Gardai

Jing Yang

Haley Neff-LaFord

Thomas John Manley

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunomodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.

Dosage and administration of non-fucosylated anti-CD40 antibodies

Growing community of inventors

Seattle, WA, United States of America

Stanford L Peng